In the letter, which was sent industry-wide, Health Canada states that “labelling practices in which the THC and CBD values displayed on the label of a cannabis product […] that have not been obtained as a result of cannabinoid testing on each lot or batch of cannabis, may result in non-compliance.”
Health Canada further writes that labels derived from “historical cultivar-based results or other practices, do not correspond to an accurate measurement of a specific lot’s THC and CBD content values, and may not correspond to the amounts the cannabis product could yield.” Dosanjh, who first contacted Health Canada about this issue last December, said he’s happy with what the letter states, but would like to see more information about the potential impact of non-compliance moving forward.Article contentDosanjh added that the discrepancies in labelling practices could amount to millions of dollars in savings and revenue for producers who were taking a static approach.
“What I believe certain producers are trying to do is indicate to consumers that the product they were buying was at a higher potency by using an average,” Dosanjh argued. “As a result, I think they probably saved millions of dollars if they were a large producer.”
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: CTVNews - 🏆 1. / 99 Read more »